Two Sigma Advisers LP Acquires 970,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Two Sigma Advisers LP boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,998,317 shares of the company's stock after buying an additional 970,700 shares during the quarter. Two Sigma Advisers LP owned approximately 1.96% of Intellia Therapeutics worth $23,300,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC raised its holdings in Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock worth $6,017,000 after purchasing an additional 44,022 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock valued at $146,174,000 after purchasing an additional 280,946 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Intellia Therapeutics by 85.7% during the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock worth $523,000 after buying an additional 20,694 shares during the period. Raymond James Financial Inc. bought a new position in Intellia Therapeutics during the fourth quarter worth $4,793,000. Finally, Baker BROS. Advisors LP acquired a new position in Intellia Therapeutics in the fourth quarter valued at $7,510,000. Institutional investors own 88.77% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NTLA. Morgan Stanley downgraded Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $56.00 to $11.00 in a research note on Monday, January 27th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Barclays cut their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday. Finally, The Goldman Sachs Group reissued a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.90.

Intellia Therapeutics Trading Up 6.7%

Intellia Therapeutics stock opened at $9.67 on Wednesday. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -1.78 and a beta of 2.33. The firm has a 50 day moving average of $7.98 and a 200 day moving average of $10.68.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. Intellia Therapeutics's revenue was down 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.12) earnings per share. On average, analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.